Development of a whole-cell screening system for evaluation of the human CYP1A2-mediated metabolism

Biotechnology and Bioengineering

Volumn 108, Issue 12, 2011, Pages 2932-2940

  Chu, Chih Chieh ^a   Pan, Kao Lu ^a   Yao, Hsien Tsung ^b   Hsu, John Tsu An ^c,d  

^a NATIONAL TSING HUA UNIVERSITY   (Taiwan)

^b CHINA MEDICAL UNIVERSITY   (Taiwan)

^c NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^d NATIONAL CHIAO TUNG UNIVERSITY   (Taiwan)

Author keywords

Cytochrome P450; Cytotoxicity; Drug metabolism

Indexed keywords

AFLATOXIN B1; CELL LINES; CELL-BASED; CELLULAR TOXICITIES; CONTROL-CELL; CYTOCHROME P450; DRUG METABOLISM; DRUG METABOLISMS; ENHANCED GREEN FLUORESCENCE PROTEINS; EXPRESSION LEVELS; HUH-7 CELLS; IN-VITRO; INTERNAL RIBOSOME ENTRY SITE; LENTIVIRAL VECTOR; SCREENING SYSTEM; STABLE CELL LINES;

AFLATOXINS; CELL CULTURE; CYTOTOXICITY; METABOLISM; PHYSIOLOGY;

CELLS;

AFLATOXIN B1; BERBERINE; CYTOCHROME P450 1A2; CYTOCHROME P450 INHIBITOR; ENHANCED GREEN FLUORESCENT PROTEIN; EVOXINE; FURAFYLLINE; LENTIVIRUS VECTOR; PLASMID LENTI 1A2 I E; THIOMERSAL; UNCLASSIFIED DRUG;

ARTICLE; CELL LINE; CELL METABOLISM; CYTOTOXICITY; DRUG METABOLISM; DRUG SCREENING; GENE CONSTRUCT; GENETIC CODE; HUMAN; HUMAN CELL; INTERNAL RIBOSOME ENTRY SITE; PROMOTER REGION; WHOLE CELL;

BERBERINE; CELL LINE; CYTOCHROME P-450 CYP1A2; DRUG EVALUATION, PRECLINICAL; DRUG TOXICITY; ENZYME INHIBITORS; HUMANS; RECOMBINANT PROTEINS; THEOPHYLLINE;

EID: 80054029537     PISSN: 00063592     EISSN: 10970290     Source Type: Journal    
DOI: 10.1002/bit.23256     Document Type: Article

References (37)

1. Bai J, Cederbaum AI. 2004. Adenovirus mediated overexpression of CYP2E1 increases sensitivity of HepG2cells to acetaminophen induced cytotoxicity. Mol Cell Biochem 262(1-2): 165-176.
2. Blight KJ, McKeating JA, Rice CM. 2002. Highly permissive cell lines for subgenomic and genomic hepatitis C virus RNA replication. J Virol 76(24): 13001-13014.
3. Buchschacher GL, Jr., Wong-Staal F. 2000. Development of lentiviral vectors for gene therapy for human diseases. Blood 95(8): 2499-2504.
4. Buttke TM, McCubrey JA, Owen TC. 1993. Use of an aqueous soluble tetrazolium/formazan assay to measure viability and proliferation of lymphokine-dependent cell lines. J Immunol Methods 157(1-2): 233-240.
5. Donato MT, Jimenez N, Castell JV, Gomez-Lechon MJ. 2004. Fluorescence-based assays for screening nine cytochrome P450 (P450) activities in intact cells expressing individual human P450 enzymes. Drug Metab Dispos 32(7): 699-706.
6. Donato MT, Lahoz A, Castell JV, Gomez-Lechon MJ. 2008. Cell lines: A tool for in vitro drug metabolism studies. Curr Drug Metab 9(1): 1-11.
7. Epifano F, Genovese S, Menghini L, Curini M. 2007. Chemistry and pharmacology of oxyprenylated secondary plant metabolites. Phytochemistry 68(7): 939-953.
8. Gallagher EP, Kunze KL, Stapleton PL, Eaton DL. 1996. The kinetics of aflatoxin B1 oxidation by human cDNA-expressed and human liver microsomal cytochromes P450 1A2 and 3A4. Toxicol Appl Pharmacol 141(2): 595-606.
9. Guengerich FP. 2008. Cytochrome p450 and chemical toxicology. Chem Res Toxicol 21(1): 70-83.
10. Klingenberg M. 1958. Pigments of rat liver microsomes. Arch Biochem Biophys 75(2): 376-386.
11. Kulkarni SK, Dhir A. 2010. Berberine: A plant alkaloid with therapeutic potential for central nervous system disorders. Phytother Res 24(3): 317-324.
12. Laika B, Leucht S, Heres S, Schneider H, Steimer W. 2010. Pharmacogenetics and olanzapine treatment: CYP1A2*1F and serotonergic polymorphisms influence therapeutic outcome. Pharmacogenomics J 10(1): 20-29.
13. Lin JH, Lu AY. 1998. Inhibition and induction of cytochrome P450 and the clinical implications. Clin Pharmacokinet 35(5): 361-390.
14. Ma X, Jiang Y, Wu A, Chen X, Pi R, Liu M, Liu Y. 2010. Berberine attenuates experimental autoimmune encephalomyelitis in C57 BL/6 mice. PLoS ONE 5(10): e13489.
15. Mace K, Aguilar F, Wang JS, Vautravers P, Gomez-Lechon M, Gonzalez FJ, Groopman J, Harris CC, Pfeifer AM. 1997. Aflatoxin B1-induced DNA adduct formation and p53 mutations in CYP450-expressing human liver cell lines. Carcinogenesis 18(7): 1291-1297.
16. Malich G, Markovic B, Winder C. 1997. The sensitivity and specificity of the MTS tetrazolium assay for detecting the in vitro cytotoxicity of 20 chemicals using human cell lines. Toxicology 124(3): 179-192.
17. Manson MM, Ball HW, Barrett MC, Clark HL, Judah DJ, Williamson G, Neal GE. 1997. Mechanism of action of dietary chemoprotective agents in rat liver: Induction of phase I and II drug metabolizing enzymes and aflatoxin B1 metabolism. Carcinogenesis 18(9): 1729-1738.
18. McDonagh PD, Judah DJ, Hayes JD, Lian LY, Neal GE, Wolf CR, Roberts GC. 1999. Determinants of specificity for aflatoxin B1-8, 9-epoxide in alpha-class glutathione S-transferases. Biochem J 339(Pt 1): 95-101.
19. Murray M. 2006. Altered CYP expression and function in response to dietary factors: Potential roles in disease pathogenesis. Curr Drug Metab 7(1): 67-81.
20. Nakabayashi H, Taketa K, Miyano K, Yamane T, Sato J. 1982. Growth of human hepatoma cells lines with differentiated functions in chemically defined medium. Cancer Res 42(9): 3858-3863.
21. Nakabayashi H, Taketa K, Yamane T, Miyazaki M, Miyano K, Sato J. 1984. Phenotypical stability of a human hepatoma cell line, HuH-7, in long-term culture with chemically defined medium. Gann 75(2): 151-158.
22. Naldini L. 1998. Lentiviruses as gene transfer agents for delivery to non-dividing cells. Curr Opin Biotechnol 9(5): 457-463.
23. Omura T, Sato R. 1962. A new cytochrome in liver microsomes. J Biol Chem 237: 1375-1376.
24. Pan KL, Lee JC, Sung HW, Chang TY, Hsu JT. 2009. Development of NS3/4A protease-based reporter assay suitable for efficiently assessing hepatitis C virus infection. Antimicrob Agents Chemother 53(11): 4825-4834.
25. Qin X, Guo BT, Wan B, Fang L, Lu L, Wu L, Zang YQ, Zhang JZ. 2010. Regulation of Th1 and Th17 cell differentiation and amelioration of experimental autoimmune encephalomyelitis by natural product compound berberine. J Immunol 185(3): 1855-1863.
26. Ramaiah SK, Apte U, Mehendale HM. 2001. Cytochrome P4502E1 induction increases thioacetamide liver injury in diet-restricted rats. Drug Metab Dispos 29(8): 1088-1095.
27. Roos PH, Jakubowski N. 2008. Cytochrome p450. Anal Bioanal Chem 392(6): 1015-1017.
28. Seki S, Kitada T, Kawada N, Sakaguchi H, Kadoya H, Nakatani K, Satake K, Kuroki T. 1999. Establishment and characteristics of human hepatocellular carcinoma cells with metastasis to lymph nodes. Hepatogastroenterology 46(29): 2812-2817.
29. Seliskar M, Rozman D. 2007. Mammalian cytochromes P450-importance of tissue specificity. Biochim Biophys Acta 1770(3): 458-466.
30. Tang C, Lin JH, Lu AY. 2005. Metabolism-based drug-drug interactions: What determines individual variability in cytochrome P450 induction? Drug Metab Dispos 33(5): 603-613.
31. Vermeir M, Annaert P, Mamidi RN, Roymans D, Meuldermans W, Mannens G. 2005. Cell-based models to study hepatic drug metabolism and enzyme induction in humans. Expert Opin Drug Metab Toxicol 1(1): 75-90.
32. Vuddanda PR, Chakraborty S, Singh S. 2010. Berberine: A potential phytochemical with multispectrum therapeutic activities. Expert Opin Investig Drugs 19(10): 1297-1307.
33. Waffo AF, Coombes PH, Crouch NR, Mulholland DA, El Amin SM, Smith PJ. 2007. Acridone and furoquinoline alkaloids from Teclea gerrardii (Rutaceae: Toddalioideae) of southern Africa. Phytochemistry 68(5): 663-667.
34. Yan QG, Shi JG, Zhang F, Zhao QT, Pang XW, Chen R, Hu PZ, Li QL, Wang Z, Huang GS. 2008. Overexpression of CYP2E1 enhances sensitivity of hepG2cells to fas-mediated cytotoxicity. Cancer Biol Ther 7(8): 1280-1287.
35. Zhang JH, Chung TD, Oldenburg KR. 1999. A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J Biomol Screen 4(2): 67-73.
36. Zhang JG, Ho T, Callendrello AL, Crespi CL, Stresser DM. 2010. A multi-endpoint evaluation of cytochrome P450 1A2, 2B6 and 3A4 induction response in human hepatocyte cultures after treatment with beta-naphthoflavone, phenobarbital and rifampicin. Drug Metab Lett 4(4): 185-194.
37. Zhou SF, Zhou ZW, Huang M. 2010. Polymorphisms of human cytochrome P450 2C9 and the functional relevance. Toxicology 278(2): 165-188.